| Literature DB >> 21782240 |
Rahel A Mathew1, John M Bennett, Jane Jijun Liu, Rami S Komrokji, Jeffrey E Lancet, Mojdeh Naghashpour, Jane L Messina, Alan F List, Lynn C Moscinski, Ling Zhang.
Abstract
Our retrospective analysis explored the role of leukemia cutis (LC) in disease progression of chronic myelomonocytic leukemia (CMML). Of 108 patients with CMML, 11 patients (10.2%) had LC including its equivalent (2 patients). Four of these patients developed acute myeloid leukemia (AML) within 0-4 months. The remaining 7 patients demonstrated increased monocytes (<20% blasts), with 3 demonstrating extramedullary involvement. Overall survival from LC to disease progression was 7.8 months. Overall survival from diagnosis to the last follow-up in patients with LC was 28.2 months, shorter than patients without LC (44 months). LC and its equivalent could predict disease progression to AML. Published by Elsevier Ltd.Entities:
Mesh：
Year: 2011 PMID： 21782240 DOI： 10.1016/j.leukres.2011.05.003
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156